Resverlogix: The Future of Drug Development
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-bas …
Developing safe, epigenetic therapeutics for people suffering from chronic illnesses
Resverlogix is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses and providing value-based health solutions to key partners.
The Company was founded in 2001 by Donald McCaffrey and Norman Wong. They're a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. They provide novel science, clinical, and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups.
For more information on Resverlogix Corp. (TSX: RVX) please click the investor request info button.
Latest Articles
Hot Companies
You might also like
BTV Showcases Contango Ore, Critical Elements Lithium, Dryden Gold, FireFox Gold, Kirkland Lake, Klondike Gold, and Selkirk Mines
This week, BTV - Business Television we feature growth-focused mining companies advancing major projects across North America and Europe. From emerging producers and strategic combinations to high-grade exploration and critical mineral development, this episode highlights the next wave of opportunity in the resource sector, including:
Selkirk Copper: A Yukon restart positioned to deliver new Canadian copper supply by 2028
A 50,000-metre drill program began last summer to expand understanding of the resource and guide updated mine design. The goal is to define a 12–15 year mine life while refreshing permits and engineering.
